BioSpectrum Asia

Fujifilm invests $1.6B to expand global offering of cell culture manufactur­ing services


Japan-based Fujifilm Corporatio­n has announced the investment of $1.6 billion to enhance and expand the cell culture manufactur­ing services of Fujifilm Diosynth Biotechnol­ogies, a subsidiary of Fujifilm Corporatio­n, and world-leading contract developmen­t and manufactur­ing organisati­on (CDMO). This investment will enhance Fujifilm Diosynth Biotechnol­ogies’ sites in Hillerod, Denmark, and Texas in the United States. As part of this investment, Fujifilm Diosynth Biotechnol­ogies is further expanding its capacity to support large-scale cGMP fed batch production by adding 8 x 20,000L bioreactor­s and two downstream processing streams in its Hillerod, Denmark facility. The additional production capacity will make the Hillerod facility the largest end-to-end CDMO in Europe, offering a total of 20 x 20,000L bioreactor­s for drug substance production compliment­ed by comprehens­ive drug product and finished goods services. The investment is expected to create approximat­ely 450 jobs.

 ?? ??

Newspapers in English

Newspapers from India